KTX 049
Alternative Names: KTX-049Latest Information Update: 19 Dec 2024
At a glance
- Originator Kymera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mdm2 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Merkel cell carcinoma
Most Recent Events
- 23 Oct 2024 Pharmacodynamics data from a preclinical studies in Merkel cell carcinoma presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 11 Oct 2023 Preclinical trials in Merkel cell carcinoma in USA (unspecified route), prior to October 2023
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Merkel cell carcinoma presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)